Laurie Stelzer
Director/Miembro de la Junta en PMV PHARMACEUTICALS, INC. .
Fortuna: - $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Mack | M | 62 | 11 años | |
Jeffrey Henderson | M | 59 | 9 años | |
Cameron Turtle | M | 34 | 1 años | |
Carol Gallagher | M | 59 | 2 años | |
Michael Carulli | M | 74 | 4 años | |
Arnold Levine | M | 84 | 11 años | |
Robert Ticktin | M | 62 | - | |
Heidy Abreu King-Jones | F | 41 | 1 años | |
Kirsten Flowers | F | 49 | 2 años | |
Michael Henderson | M | 34 | 1 años | |
Richard Heyman | M | 66 | 4 años | |
Scott Burrows | M | 47 | 1 años | |
Bernadette Connaughton | F | 65 | 6 años | |
Brian Goodman | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Charles Baum | M | 65 | 3 años | |
Deepika Jalota | M | 48 | 5 años | |
Tomas Kiselak | M | 38 | 1 años | |
Timothy J. Smith | M | - | 3 años | |
Tyler Jacks | M | 63 | 12 años | |
Amit Munshi | M | 56 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Peter Harwin | M | 38 | 1 años | |
Lauren Harshman | F | - | 3 años | |
Deanna Nguyen | M | - | 1 años | |
Marc Fellous | M | - | 2 años | |
Mira Huyghe | F | - | 1 años | |
Crystal Zuckerman | F | - | 4 años | |
Shibu Sleeba | M | - | 4 años | |
Laura De Leon | F | - | 5 años | |
Joshua Friedman | M | - | 1 años | |
Ciaran Lawlor | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 años |
Amy Marinne Fox | F | - | 4 años | |
Lamine Mbow | M | - | 3 años | |
Steve Knowles | M | - | 6 años | |
Paul Fehlner | M | 61 | 1 años | |
Mark Mckenna | M | 48 | - | |
Binh Vu | M | 56 | - | |
Scott W. Rowlinson | M | 56 | 10 años | |
Jeffrey Albers | M | 52 | 1 años | |
Matt Roden | M | 53 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 1 años |
Morana Jovan-Embiricos | M | 57 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Brian Connolly | M | - | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Laurie Stelzer
- Red Personal